|
Variable
|
Low prescriber group (OR, 95 % CI)
|
High prescriber group (OR, 95 % CI)
|
p value**
|
|---|
|
Demographics
| | | |
|
Age (decades)
|
1.15, 1.11–1.20*
|
1.26, 1.23–1.29*
|
<0.001
|
|
Gender (female)
|
0.98, 0.87–1.10
|
0.89, 0.82–0.97*
|
0.211
|
|
Current smoker (versus never)
|
1.09, 1.02–1.17*
|
1.07, 1.02–1.13*
|
0.744
|
|
GC-associated comorbidities
| | | |
|
Osteoporosis
|
1.49, 1.14–1.95*
|
1.84, 1.50–2.25*
|
0.225
|
|
Avascular necrosis
|
2.28, 0.32–16.22
|
1.84, 0.36–9.51
|
0.870
|
|
Myopathy
|
2.29, 0.57–9.15
|
1.23, 0.45–3.38
|
0.479
|
|
Diabetes mellitus
|
0.88, 0.72–1.08
|
1.02, 0.88–1.18
|
0.257
|
|
Cardiovascular disease
|
1.38, 1.04–1.84*
|
1.62, 1.31–2.00*
|
0.373
|
|
Hypertension
|
1.08, 0.95–1.24
|
1.29, 1.17–1.41*
|
0.039
|
|
Hyperlipidaemia
|
1.10, 0.92–1.31
|
1.07, 0.94–1.22
|
0.829
|
|
Peptic ulcer disease
|
1.36, 1.06–1.74*
|
1.33, 1.09–1.63*
|
0.910
|
|
Pancreatitis
|
1.00, 0.49–2.05
|
1.44, 0.81–2.54
|
0.442
|
|
Depression
|
1.09, 0.96–1.23
|
1.09, 0.99–1.20
|
0.994
|
|
Insomnia
|
1.27, 1.08–1.50*
|
1.36, 1.20–1.54*
|
0.548
|
|
Psychosis
|
1.14, 0.60–2.17
|
1.29, 0.78–2.14
|
0.767
|
|
Prior use
| | | |
|
GC prescription prior to follow up
|
6.52, 5.51–7.71*
|
11.76, 10.24–13.51*
|
<0.001
|
-
GC glucocorticoid, OR odds ratio, CI confidence interval
-
*Significant predictors of GC prescriptions (unadjusted)
-
**
p value indicates significance of any differing effect between high and low prescriber groups
